세계의 핵의학 장비 시장 : 시스템 유형별, 치료 분야별, 차원별, 최종사용자별, 지역별 - 예측(-2030년)

Nuclear Medicine Equipment Market by Product (Imaging: PET, SPECT, Gamma; GM Counter, Dose Calibrator), Software (Image Management, PACS, Treatment, Analytic, Workflow), Therapy (Onco, Cardio, Neuro, Ortho), End User & Region - Global Forecasts to 2030

US $ 4,950 ￦ 6,951,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,650 ￦ 9,339,000

PDF (5-user License)

PDF 보고서를 동일 사업장에서 5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,150 ￦ 11,445,000

PDF (Corporate License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 이용 인원에 제한은 없으나, 국내에 있는 사업장만 해당되며, 해외 지점 등은 포함되지 않습니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,000 ￦ 14,044,000

PDF (Global License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. (100% 자회사는 동일 기업으로 간주됩니다.) 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

핵의학 장비 시장 규모는 2025년에 66억 3,000만 달러로 평가되었고, 2030년에는 83억 1,000만 달러에 이를 것으로 예측되며, 예측 기간 중 연평균 복합 성장률(CAGR)은 4.62%를 보일 전망입니다.

암, 심혈관 질환 등 만성질환의 유병률 증가와 조기 및 정확한 영상진단에 대한 수요 증가가 핵의학 장비 시장 성장을 가속하고 있습니다.

조사 범위
조사 대상 연도	2024-2030년
기준 연도	2024년
예측 기간	2025-2030년
검토 단위	금액(10억 달러)
부문	시스템 유형별, 치료 분야별, 차원별, 최종사용자별, 지역별
대상 지역	북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카

또한, 개인 맞춤형 의료에 대한 인식 증가, 방사성의약품의 용도 확대, 정부 지원책, 방사성의약품에 대한 접근성 개선 등이 시장 성장에 기여하고 있습니다. AI 통합, 모바일/원격 접속 등의 기술 혁신은 진단 효율을 향상시키고, 시장 진출기업에게 큰 비즈니스 기회를 제공할 것으로 보입니다.

차원별로는 2024년 3D 부문이 핵의학 기기 시장에서 가장 큰 점유율을 차지할 것으로 예측됩니다. 이는 3D 시스템의 뛰어난 이미징 능력으로 인해 2D 이미징보다 더 높은 공간 해상도, 더 상세한 해부학적 디테일, 더 정확한 병변 국소화를 제공합니다. 이러한 장점은 정확한 시각화가 진단, 병기 결정, 치료 계획에 필수적인 종양학, 심장학, 신경학에서 특히 유용합니다. PET/CT 및 SPECT/CT와 같이 기본적으로 3D 영상을 제공하는 첨단 영상기법의 채택이 증가하고 정량적 영상 및 맞춤 치료 접근법에 대한 수요가 증가함에 따라 3D 부문의 우위에 기여하고 있습니다.

2024년 핵의학 기기 시장은 북미 시장이 독점했습니다. 이러한 우위는 첨단 의료 인프라와 핵의학 시술의 보급 등 다양한 요인에 의해 가속화되고 있습니다. 미국 학술원(NCBI)의 보고에 따르면, 방사성의약품과 영상진단기기를 이용한 핵의학 시술은 미국에서만 연간 2,000만 건 가까이 시행되고 있으며, 하이브리드 PET/CT와 SPECT/CT 시스템의 성장이 증가하고 있다고 합니다. 또한, 만성질환, 특히 암 증가는 2024년까지 미국에서 200만 명 이상의 신규 환자와 612만 명의 사망자를 차지할 것으로 예측되고 있어, 북미에서는 조기에 정확한 진단 기술이 더욱 중요해지고 있습니다. 세계 핵의학 기기 시장에서 북미가 우위를 점하고 있는 주요 요인은 유리한 상환 정책, 민관 양 부문의 막대한 연구개발비, GE Healthcare, Siemens Healthineers, Cardinal Health 등 주요 업계 진출 기업의 존재 등입니다.

세계의 핵의학 기기 시장에 대해 조사했으며, 시스템 유형별, 치료 분야별, 차원별, 최종사용자별, 지역별 동향, 시장 진출기업 프로파일 등의 정보를 정리하여 전해드립니다.

목차

제1장 서론

제2장 조사 방법

제3장 주요 요약

제4장 프리미엄 인사이트

제5장 시장 개요

• 서론
• 시장 역학
• 고객의 비즈니스에 영향을 미치는 동향/혼란
• 업계 동향
• 가격 분석
• 밸류체인 분석
• 생태계 분석
• 투자 및 자금조달 시나리오
• 기술 분석
• 특허 분석
• 무역 분석
• 2025년-2026년 주요 컨퍼런스 및 이벤트
• 사례 연구 분석
• 관세 및 규제 상황
• Porter의 Five Forces 분석
• 주요 이해관계자와 구입 기준
• 최종사용자 분석
• 비즈니스 모델
• AI/생성형 AI의 영향
• 2025년 미국 관세의 영향-개요

제6장 핵의학 장비 시장(시스템 유형별)

• 서론
• 영상 진단 장비
• 비영상 진단법

제7장 핵의학 장비 시장(치료 분야별)

• 서론
• 종양과
• 신경과
• 심장병과
• 정형외과
• 갑상선
• 기타

제8장 핵의학 장비 시장(차원별)

• 서론
• 2D
• 3D

제9장 핵의학 장비 시장(최종사용자별)

• 서론
• 병원
• 진단영상센터
• 암 치료센터
• 기타

제10장 핵의학 장비 시장(지역별)

• 서론
• 북미
  • 북미의 거시경제 전망
  • 미국
  • 캐나다
• 유럽
  • 유럽의 거시경제 전망
  • 독일
  • 영국
  • 프랑스
  • 이탈리아
  • 스페인
  • 스웨덴
  • 기타
• 아시아태평양
  • 아시아태평양의 거시경제 전망
  • 일본
  • 중국
  • 인도
  • 한국
  • 호주
  • 기타
• 중동 및 아프리카
  • 중동 및 아프리카의 거시경제 전망
  • GCC 국가
  • 기타
• 라틴아메리카
  • 라틴아메리카의 거시경제 전망
  • 브라질
  • 멕시코
  • 기타

제11장 경쟁 구도

• 개요
• 주요 시장 진출기업의 전략
• 매출 분석, 2020년-2024년
• 시장 점유율 분석, 2024년
• 시장 순위 분석
• 브랜드/제품 비교
• 기업 평가와 재무 지표
• 기업 평가 매트릭스 : 주요 시장 진출기업, 2024년
• 기업 평가 매트릭스 : 스타트업/중소기업, 2024년
• 경쟁 시나리오

제12장 기업 개요

• 주요 시장 진출기업
  • GE HEALTHCARE
  • SIEMENS HEALTHINEERS AG
  • KONINKLIJKE PHILIPS N.V.
  • MIRION TECHNOLOGIES, INC.
  • CANON MEDICAL SYSTEMS CORPORATION
  • HERMES MEDICAL SOLUTIONS
  • DOSISOFT SA
  • SEGAMI CORPORATION
  • WINKGEN MEDICAL SYSTEMS GMBH & CO. KG
  • COMECER S.P.A.
  • SYNTERMED INC.
  • ULTRASPECT INC.
  • LABLOGIC SYSTEMS LTD.
  • MEDISO LTD.
  • CATALYST MEDTECH
  • LEMER PAX
  • SPECTRUM DYNAMICS MEDICAL
  • NEUSOFT MEDICAL SYSTEMS CO., LTD.
  • BRAINLAB SE
  • MIRADA MEDICAL
• 기타 기업
  • TRASIS
  • SOFIE
  • ITM ISOTOPE TECHNOLOGIES MUNICH SE
  • POSITRIGO AG
  • PAIRE

제13장 부록

LSH

영문 목차

영문목차

The nuclear medicine equipment market was valued at USD 6.63 billion in 2025 and is estimated to reach USD 8.31 billion by 2030, registering a CAGR of 4.62% during the forecast period. The growing prevalence of chronic diseases such as cancer and cardiovascular disorders, as well as the rising demand for early and accurate diagnostic imaging, are driving market growth in nuclear medicine equipment.

Scope of the Report
Years Considered for the Study	2024-2030
Base Year	2024
Forecast Period	2025-2030
Units Considered	Value (USD billion)
Segments	Product Type, Therapeutic Area, Dimension, End User, Region
Regions covered	North America, Europe, APAC, LATAM, MEA

Furthermore, increased awareness of personalized medicine, expanded applications of radiotheranostics, supportive government initiatives, and improved access to radiopharmaceuticals are all contributing to market growth. Technological innovations, such as AI integration and mobile/remote access, will improve diagnostic efficiency and create significant opportunities for market players.

The 3D segment dominated the nuclear medicine equipment market, by dimension, in 2024.

Based on dimension, the 3D segment is expected to hold the largest share of the nuclear medicine equipment market in 2024. This is due to the superior imaging capabilities of 3D systems, which provide higher spatial resolution, greater anatomical detail, and more accurate localization of lesions than 2D imaging. These benefits are especially useful in oncology, cardiology, and neurology, where accurate visualization is essential for diagnosis, staging, and treatment planning. The growing adoption of advanced modalities such as PET/CT and SPECT/CT, which provide 3D imaging by default, combined with rising demand for quantitative imaging and personalized treatment approaches, contributes to the 3D segment's dominance.

The North American market accounted for the largest share in the nuclear medicine equipment market in 2024.

The North American market dominated the nuclear medicine equipment market in 2024. This dominance is accelerated by various factors such as advanced healthcare infrastructure and the widespread use of nuclear medicine procedures. The US National Academies (NCBI) report that nearly 20 million nuclear medicine procedures using radiopharmaceuticals and imaging instruments are carried out annually in the US alone, with increasing growth in hybrid PET/CT and SPECT/CT systems. Moreover, the rise in chronic diseases, especially cancer, which is predicted to account for over 2 million new cases and 6,12,000 deaths in the US by 2024, makes early and accurate diagnosis technologies even more crucial in North America. The main factors contributing to North America's dominance in the global nuclear medicine equipment market are favorable reimbursement policies, substantial R&D spending by both the public and private sectors, and the presence of major industry players such as GE Healthcare, Siemens Healthineers, and Cardinal Health.

In-depth interviews have been conducted with chief executive officers (CEOs), Directors, and other executives from various key organizations operating in the nuclear medicine equipment marketplace.

The breakdown of primary participants is as mentioned below:

• By Company Type - Tier 1 (41%), Tier 2 (31%), and Tier 3 (28%)
• By Designation - C-level (44%), Directors (31%), and Others (25%)
• By Region - North America (45%), Europe (28%), Asia Pacific (20%), Latin America (4%), Middle East & Africa (3%)

Key Players in the Nuclear Medicine Equipment Market

Prominent players in the nuclear medicine equipment market include Hermes Medical Solutions (Sweden), DOSIsoft (France), Segami Corporation (US), GE HealthCare (US), Siemens Healthineers AG (Germany), Koninklijke Philips N.V. (Netherlands), Mirion Technologies, Inc. (US), Comecer S.p.A. (Italy), Syntermed (US), UltraSPECT Inc. (US), LabLogic Systems Ltd. (UK), Mediso Ltd. (Hungary), CANON MEDICAL SYSTEMS CORPORATION (Japan), Catalyst Medtech (US), Lemer Pax (France), Spectrum Dynamics Medical (US), Neusoft Medical Systems Co., Ltd. (China), Brainlab AG(Germany), Mirada Medical(UK), Trasis (Belgium), SOFIE (US), ITM Isotope Technologies Munich SE (Germany), Positrigo AG (Switzerland), PAIRE (France).

Players adopted organic as well as inorganic growth strategies such as product launches and enhancements, and investments, partnerships, collaborations, joint ventures, funding, acquisition, expansions, agreements, contracts, and alliances to increase their offerings, cater to the unmet needs of customers, increase their profitability, and expand their presence in the global market.

The study includes an in-depth competitive analysis of these key players in the nuclear medicine equipment market, with their company profiles, recent developments, and key market strategies.

Research Coverage

• The report studies the nuclear medicine equipment market based on product type, therapeutic area, dimension, end user, and region.
• The report analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth.
• The report evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders.
• The report studies micro-markets with respect to their growth trends, prospects, and contributions to the total nuclear medicine equipment market.
• The report forecasts the revenue of market segments with respect to five major regions.

Reasons to Buy the Report

The report can help established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one or a combination of the following five strategies.

This report provides insights into the following pointers:

• Analysis of key drivers (rising prevalence of cancer and cardiovascular diseases, technological advancements in hybrid imaging systems, growing demand for personalized medicines and theranostics), restraints (high cost of nuclear medicine equipment and imaging procedures, limited availability and short shelf-life of radiopharmaceuticals), opportunities (development of novel radiotracers and targeted imaging agents, integration of AI and data analytics in imaging workflows), and challenges (stringent regulatory approval processes for equipment and radiopharmaceuticals, shortage of skilled nuclear medicine professionals, radioactive waste management and safety concerns) influencing the industry macro dynamics of nuclear medicine equipment market.
• Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and product launches in the nuclear medicine equipment market.
• Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various types of nuclear medicine equipment across regions.
• Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in the nuclear medicine equipment market.
• Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the nuclear medicine equipment market.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE
  • 1.3.2 INCLUSIONS AND EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
• 1.4 CURRENCY CONSIDERED
• 1.5 STAKEHOLDERS

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH APPROACH
  • 2.1.1 SECONDARY RESEARCH
    • 2.1.1.1 Key data from secondary sources
  • 2.1.2 PRIMARY RESEARCH
    • 2.1.2.1 Primary sources
    • 2.1.2.2 Key data from primary sources
    • 2.1.2.3 Breakdown of primary interviews
    • 2.1.2.4 Insights from primary experts
• 2.2 RESEARCH METHODOLOGY
• 2.3 MARKET SIZE ESTIMATION
• 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
• 2.5 MARKET SHARE ESTIMATION
• 2.6 RESEARCH ASSUMPTIONS
• 2.7 RESEARCH LIMITATIONS
• 2.8 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 OVERVIEW OF NUCLEAR MEDICINE EQUIPMENT MARKET
• 4.2 ASIA PACIFIC: NUCLEAR MEDICINE EQUIPMENT MARKET, BY THERAPEUTIC AREA
• 4.3 GEOGRAPHIC SNAPSHOT OF NUCLEAR MEDICINE EQUIPMENT MARKET
• 4.4 NUCLEAR MEDICINE EQUIPMENT MARKET: REGIONAL MIX
• 4.5 NUCLEAR MEDICINE EQUIPMENT MARKET: DEVELOPED VS. EMERGING MARKETS

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Rapid expansion of theranostics
    • 5.2.1.2 Technological advancements in hybrid imaging modalities
    • 5.2.1.3 Favorable government support and expanding healthcare infrastructure
    • 5.2.1.4 Advancements in radiotracers and radiopharmaceuticals
    • 5.2.1.5 Integration of AI into nuclear medicine equipment
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Capital-intensive nature of equipment
    • 5.2.2.2 Short half-life of radiopharmaceuticals
    • 5.2.2.3 High maintenance and operational costs
    • 5.2.2.4 Shortage of trained personnel
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Growing preference for personalized and precision medicine
    • 5.2.3.2 Telemedicine and cloud-native platforms & mobile/remote imaging capabilities
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Global isotope supply chain instability
    • 5.2.4.2 Cybersecurity and data privacy issues in imaging IT
• 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
• 5.4 INDUSTRY TRENDS
  • 5.4.1 SHIFT TOWARD HYBRID AND MULTI-MODALITY IMAGING SYSTEMS
  • 5.4.2 ADVANCEMENTS IN DETECTOR TECHNOLOGIES AND IMAGE QUALITY
  • 5.4.3 GROWING DEMAND FOR COMPACT AND VERSATILE SYSTEMS
  • 5.4.4 INTEGRATION OF ARTIFICIAL INTELLIGENCE AND AUTOMATION
  • 5.4.5 CONNECTIVITY AND CLOUD-ENABLED WORKFLOWS
• 5.5 PRICING ANALYSIS
  • 5.5.1 INTRODUCTION
  • 5.5.2 INDICATIVE PRICE OF NUCLEAR MEDICINE EQUIPMENT, BY KEY PLAYER
  • 5.5.3 INDICATIVE PRICE OF NUCLEAR MEDICINE EQUIPMENT, BY REGION
  • 5.5.4 AVERAGE SELLING PRICE OF NUCLEAR CARDIOLOGY REPORTING SOFTWARE
  • 5.5.5 PRICING MODELS
• 5.6 VALUE CHAIN ANALYSIS
• 5.7 ECOSYSTEM ANALYSIS
• 5.8 INVESTMENT AND FUNDING SCENARIO
• 5.9 TECHNOLOGY ANALYSIS
  • 5.9.1 KEY TECHNOLOGIES
    • 5.9.1.1 Hybrid imaging systems
    • 5.9.1.2 Digital detection technology
    • 5.9.1.3 Artificial Intelligence (AI) and advanced image reconstruction techniques
    • 5.9.1.4 Time-of-Flight (TOF) technology
    • 5.9.1.5 Solid-state detector technology
  • 5.9.2 COMPLEMENTARY TECHNOLOGIES
    • 5.9.2.1 Radiopharmaceutical development and theranostics
    • 5.9.2.2 Advanced computing and big data analytics
    • 5.9.2.3 Robotics and automated dose dispensing systems
  • 5.9.3 ADJACENT TECHNOLOGIES
    • 5.9.3.1 Magnetic Resonance Imaging (MRI) integration
    • 5.9.3.2 Computed Tomography (CT) advancements
• 5.10 PATENT ANALYSIS
• 5.11 TRADE ANALYSIS
  • 5.11.1 IMPORT DATA FOR HS CODE 901814
  • 5.11.2 EXPORT DATA FOR HS CODE 901814
• 5.12 KEY CONFERENCES AND EVENTS, 2025-2026
• 5.13 CASE STUDY ANALYSIS
  • 5.13.1 PRECISION IN NUCLEAR MEDICINE WITH NATIONAL STANDARD TRACEABILITY
  • 5.13.2 MULTI-MODALITY IMAGE FUSION FOR IMPROVED DIAGNOSTICS
  • 5.13.3 REMOTE CONSULTATION WITH CLOUD-BASED NUCLEAR MEDICINE ANALYSIS
• 5.14 TARIFF AND REGULATORY LANDSCAPE
  • 5.14.1 TARIFF DATA FOR HS CODE 901814
  • 5.14.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.14.3 REGULATORY ANALYSIS
• 5.15 PORTER'S FIVE FORCES ANALYSIS
  • 5.15.1 BARGAINING POWER OF SUPPLIERS
  • 5.15.2 BARGAINING POWER OF BUYERS
  • 5.15.3 THREAT OF NEW ENTRANTS
  • 5.15.4 THREAT OF SUBSTITUTES
  • 5.15.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.16 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.16.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.16.2 BUYING CRITERIA
• 5.17 END-USER ANALYSIS
  • 5.17.1 UNMET NEEDS
  • 5.17.2 END-USER EXPECTATIONS
• 5.18 BUSINESS MODEL
  • 5.18.1 DIRECT EQUIPMENT SALES MODEL
  • 5.18.2 SERVICE AND MAINTENANCE CONTRACTS
  • 5.18.3 PAY-PER-SCAN (OR PAY-PER-USE) MODEL
  • 5.18.4 EQUIPMENT LEASING AND FINANCING SOLUTIONS
  • 5.18.5 INTEGRATED SOLUTIONS AND MANAGED SERVICES
  • 5.18.6 SOFTWARE AND DATA ANALYTICS SUBSCRIPTION
• 5.19 IMPACT OF AI/GEN AI
  • 5.19.1 INTRODUCTION
  • 5.19.2 MARKET POTENTIAL OF AI/GEN AI
  • 5.19.3 CASE STUDIES RELATED TO AI/GEN AI IMPLEMENTATION
    • 5.19.3.1 AI-based low-dose PET image reconstruction
    • 5.19.3.2 Dose-aware diffusion models for 3D low-dose PET
  • 5.19.4 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS
    • 5.19.4.1 Medical image analysis software
    • 5.19.4.2 Radiology information systems
    • 5.19.4.3 Clinical decision support systems
  • 5.19.5 USER READINESS AND IMPACT ASSESSMENT
    • 5.19.5.1 User readiness
      • 5.19.5.1.1 User A: Hospitals
      • 5.19.5.1.2 User B: Diagnostic imaging centers
    • 5.19.5.2 Impact assessment
      • 5.19.5.2.1 User A: Hospitals
      • 5.19.5.2.2 User B: Diagnostic imaging centers
• 5.20 IMPACT OF 2025 US TARIFF - OVERVIEW
  • 5.20.1 INTRODUCTION
  • 5.20.2 KEY TARIFF RATES
  • 5.20.3 PRICE IMPACT ANALYSIS
    • 5.20.3.1 Capital equipment (cyclotrons, PET/SPECT systems)
    • 5.20.3.2 Gamma cameras
    • 5.20.3.3 Key materials: semiconductors, detectors, shielding
    • 5.20.3.4 Service parts, maintenance, and global supply chains
  • 5.20.4 IMPACT ON COUNTRY/REGION
    • 5.20.4.1 US
    • 5.20.4.2 Europe
    • 5.20.4.3 Asia Pacific
  • 5.20.5 IMPACT ON END-USE INDUSTRIES
    • 5.20.5.1 Hospitals
    • 5.20.5.2 Diagnostic imaging centers
    • 5.20.5.3 Cancer treatment centers
    • 5.20.5.4 Other end users
  • 5.20.6 CONCLUSION

6 NUCLEAR MEDICINE EQUIPMENT MARKET, BY SYSTEM TYPE

• 6.1 INTRODUCTION
• 6.2 IMAGING MODALITIES
  • 6.2.1 PET
    • 6.2.1.1 Standalone PET
      • 6.2.1.1.1 Increasing demand for cost-efficient, high-throughput oncological imaging to boost market
    • 6.2.1.2 Hybrid PET
      • 6.2.1.2.1 Ability to provide functional and anatomical information in single scan to aid growth
  • 6.2.2 SPECT
    • 6.2.2.1 Standalone SPECT
      • 6.2.2.1.1 Wide use in thyroid studies, renal scans, and bone imaging to encourage growth
    • 6.2.2.2 Hybrid SPECT
      • 6.2.2.2.1 Need for improved diagnostic accuracy and clinical confidence to propel market
  • 6.2.3 GAMMA/SCINTILLATION CAMERAS
    • 6.2.3.1 Clinical versatility and lower cost to expedite growth
• 6.3 NON-IMAGING MODALITIES
  • 6.3.1 GM COUNTERS
    • 6.3.1.1 Ease of use, portability, and critical role in maintaining workplace safety to spur growth
  • 6.3.2 DOSE CALIBRATORS
    • 6.3.2.1 Increasing development in digital interfaces, automatic isotope recognition, and real-time data logging to bolster growth
  • 6.3.3 PROBE COUNTING SYSTEMS
    • 6.3.3.1 Technological advancements in probe counting systems to contribute to growth
  • 6.3.4 GAMMA WELL COUNTERS
    • 6.3.4.1 Growing use of gamma well counters in laboratory-based applications to propel market
  • 6.3.5 OTHER NON-IMAGING MODALITIES

7 NUCLEAR MEDICINE EQUIPMENT MARKET, BY THERAPEUTIC AREA

• 7.1 INTRODUCTION
• 7.2 ONCOLOGY
  • 7.2.1 IMPROVEMENTS IN IMAGING ACCURACY AND TREATMENT PLANNING TO STIMULATE GROWTH
• 7.3 NEUROLOGY
  • 7.3.1 ESCALATING GLOBAL BURDEN OF NEURODEGENERATIVE DISORDERS AND OTHER NEUROLOGICAL CONDITIONS TO AID GROWTH
• 7.4 CARDIOLOGY
  • 7.4.1 PERSISTENT GLOBAL BURDEN OF CARDIOVASCULAR DISEASES TO FACILITATE GROWTH
• 7.5 ORTHOPEDICS
  • 7.5.1 GROWING PREVALENCE OF DEGENERATIVE JOINT DISEASES, SPORTS INJURIES, AND OSTEOPOROSIS TO BOOST MARKET
• 7.6 THYROID
  • 7.6.1 GLOBAL PREVALENCE OF HYPER- AND HYPOTHYROIDISM AND THYROID CANCER TO AUGMENT GROWTH
• 7.7 OTHER THERAPEUTIC AREAS

8 NUCLEAR MEDICINE EQUIPMENT MARKET, BY DIMENSION

• 8.1 INTRODUCTION
• 8.2 2D
  • 8.2.1 WIDE AVAILABILITY, EASE OF INTEGRATION, AND ESTABLISHED PRESENCE IN CLINICAL WORKFLOW TO AID GROWTH
• 8.3 3D
  • 8.3.1 GROWING RELIANCE ON ADVANCED IMAGING TECHNOLOGIES TO FUEL MARKET

9 NUCLEAR MEDICINE EQUIPMENT MARKET, BY END USER

• 9.1 INTRODUCTION
• 9.2 HOSPITALS
  • 9.2.1 CONTINUOUS TECHNOLOGICAL ADVANCEMENTS TO FOSTER GROWTH
• 9.3 DIAGNOSTIC IMAGING CENTERS
  • 9.3.1 GROWING DEMAND FOR EARLY AND PRECISE DIAGNOSIS TO DRIVE MARKET
• 9.4 CANCER TREATMENT CENTERS
  • 9.4.1 ESCALATING GLOBAL INCIDENCE OF CANCER TO PROMOTE GROWTH
• 9.5 OTHER END USERS

10 NUCLEAR MEDICINE EQUIPMENT MARKET, BY REGION

• 10.1 INTRODUCTION
• 10.2 NORTH AMERICA
  • 10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 10.2.2 US
    • 10.2.2.1 Advancements in PET and SPECT equipment for personalized care to aid growth
  • 10.2.3 CANADA
    • 10.2.3.1 Increasing adoption of advanced imaging technologies to support growth
• 10.3 EUROPE
  • 10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 10.3.2 GERMANY
    • 10.3.2.1 Increasing adoption of hybrid imaging systems to spur growth
  • 10.3.3 UK
    • 10.3.3.1 Favorable clinical guidelines supporting wider use of PET-CT to fuel market
  • 10.3.4 FRANCE
    • 10.3.4.1 Shift to hybrid imaging to accelerate growth
  • 10.3.5 ITALY
    • 10.3.5.1 Robust network of scanners to facilitate growth
  • 10.3.6 SPAIN
    • 10.3.6.1 Growing integration of cutting-edge technologies into clinical practice to propel market
  • 10.3.7 SWEDEN
    • 10.3.7.1 Rapid shift toward PET procedures to accelerate growth
  • 10.3.8 REST OF EUROPE
• 10.4 ASIA PACIFIC
  • 10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 10.4.2 JAPAN
    • 10.4.2.1 Ongoing innovations in equipment and growing reliance on nuclear imaging for accurate detection to drive market
  • 10.4.3 CHINA
    • 10.4.3.1 Rapid investments in medical infrastructure and technological advancements in image analysis to spur growth
  • 10.4.4 INDIA
    • 10.4.4.1 Substantial cancer and cardiovascular disease burden to encourage growth
  • 10.4.5 SOUTH KOREA
    • 10.4.5.1 Universal health coverage to bolster growth
  • 10.4.6 AUSTRALIA
    • 10.4.6.1 Strong diagnostic imaging network and widespread adoption of hybrid imaging technologies to contribute to growth
  • 10.4.7 REST OF ASIA PACIFIC
• 10.5 MIDDLE EAST & AFRICA
  • 10.5.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
  • 10.5.2 GCC COUNTRIES
    • 10.5.2.1 Growing healthcare needs and favorable government support to boost market
  • 10.5.3 REST OF MIDDLE EAST & AFRICA
• 10.6 LATIN AMERICA
  • 10.6.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 10.6.2 BRAZIL
    • 10.6.2.1 Healthcare modernization efforts to accelerate growth
  • 10.6.3 MEXICO
    • 10.6.3.1 Expanding healthcare infrastructure to bolster growth
  • 10.6.4 REST OF LATIN AMERICA

11 COMPETITIVE LANDSCAPE

• 11.1 OVERVIEW
• 11.2 KEY PLAYER STRATEGIES
  • 11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN NUCLEAR MEDICINE EQUIPMENT MARKET
• 11.3 REVENUE ANALYSIS, 2020-2024
• 11.4 MARKET SHARE ANALYSIS, 2024
  • 11.4.1 POSITRON EMISSION TOMOGRAPHY (PET) EQUIPMENT
  • 11.4.2 SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) EQUIPMENT
• 11.5 MARKET RANKING ANALYSIS
• 11.6 BRAND/PRODUCT COMPARISON
• 11.7 COMPANY VALUATION AND FINANCIAL METRICS
• 11.8 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 11.8.1 STARS
  • 11.8.2 EMERGING LEADERS
  • 11.8.3 PERVASIVE PLAYERS
  • 11.8.4 PARTICIPANTS
  • 11.8.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 11.8.5.1 Company footprint
    • 11.8.5.2 Region footprint
    • 11.8.5.3 System type footprint
    • 11.8.5.4 Therapeutic area footprint
    • 11.8.5.5 Dimension footprint
    • 11.8.5.6 End-user footprint
• 11.9 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  • 11.9.1 PROGRESSIVE COMPANIES
  • 11.9.2 RESPONSIVE COMPANIES
  • 11.9.3 DYNAMIC COMPANIES
  • 11.9.4 STARTING BLOCKS
  • 11.9.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
    • 11.9.5.1 Detailed list of key startups/SMEs
    • 11.9.5.2 Competitive benchmarking of startups/SMEs
• 11.10 COMPETITIVE SCENARIO
  • 11.10.1 PRODUCT LAUNCHES AND APPROVALS
  • 11.10.2 DEALS
  • 11.10.3 EXPANSIONS
  • 11.10.4 OTHER DEVELOPMENTS

12 COMPANY PROFILES

• 12.1 KEY PLAYERS
  • 12.1.1 GE HEALTHCARE
    • 12.1.1.1 Business overview
    • 12.1.1.2 Products offered
    • 12.1.1.3 Recent developments
      • 12.1.1.3.1 Product launches and approvals
      • 12.1.1.3.2 Deals
      • 12.1.1.3.3 Expansions
    • 12.1.1.4 MnM view
      • 12.1.1.4.1 Right to win
      • 12.1.1.4.2 Strategic choices
      • 12.1.1.4.3 Weaknesses and competitive threats
  • 12.1.2 SIEMENS HEALTHINEERS AG
    • 12.1.2.1 Business overview
    • 12.1.2.2 Products offered
    • 12.1.2.3 Recent developments
      • 12.1.2.3.1 Product launches and approvals
      • 12.1.2.3.2 Deals
    • 12.1.2.4 MnM view
      • 12.1.2.4.1 Right to win
      • 12.1.2.4.2 Strategic choices
      • 12.1.2.4.3 Weaknesses and competitive threats
  • 12.1.3 KONINKLIJKE PHILIPS N.V.
    • 12.1.3.1 Business overview
    • 12.1.3.2 Products offered
    • 12.1.3.3 Recent developments
      • 12.1.3.3.1 Product launches and approvals
      • 12.1.3.3.2 Deals
    • 12.1.3.4 MnM view
      • 12.1.3.4.1 Right to win
      • 12.1.3.4.2 Strategic choices
      • 12.1.3.4.3 Weaknesses and competitive threats
  • 12.1.4 MIRION TECHNOLOGIES, INC.
    • 12.1.4.1 Business overview
    • 12.1.4.2 Products offered
    • 12.1.4.3 Recent developments
      • 12.1.4.3.1 Product launches and approvals
      • 12.1.4.3.2 Deals
    • 12.1.4.4 MnM view
      • 12.1.4.4.1 Right to win
      • 12.1.4.4.2 Strategic choices
      • 12.1.4.4.3 Weaknesses and competitive threats
  • 12.1.5 CANON MEDICAL SYSTEMS CORPORATION
    • 12.1.5.1 Business overview
    • 12.1.5.2 Products offered
    • 12.1.5.3 Recent developments
      • 12.1.5.3.1 Deals
    • 12.1.5.4 MnM view
      • 12.1.5.4.1 Right to win
      • 12.1.5.4.2 Strategic choices
      • 12.1.5.4.3 Weaknesses and competitive threats
  • 12.1.6 HERMES MEDICAL SOLUTIONS
    • 12.1.6.1 Business overview
    • 12.1.6.2 Products offered
    • 12.1.6.3 Recent developments
      • 12.1.6.3.1 Product launches and approvals
      • 12.1.6.3.2 Deals
      • 12.1.6.3.3 Other developments
  • 12.1.7 DOSISOFT SA
    • 12.1.7.1 Business overview
    • 12.1.7.2 Products offered
    • 12.1.7.3 Recent developments
      • 12.1.7.3.1 Product launches and approvals
      • 12.1.7.3.2 Deals
  • 12.1.8 SEGAMI CORPORATION
    • 12.1.8.1 Business overview
    • 12.1.8.2 Products offered
  • 12.1.9 WINKGEN MEDICAL SYSTEMS GMBH & CO. KG
    • 12.1.9.1 Business overview
    • 12.1.9.2 Products offered
    • 12.1.9.3 Recent developments
      • 12.1.9.3.1 Product launches and approvals
      • 12.1.9.3.2 Deals
  • 12.1.10 COMECER S.P.A.
    • 12.1.10.1 Business overview
    • 12.1.10.2 Products offered
    • 12.1.10.3 Recent developments
      • 12.1.10.3.1 Product launches and approvals
      • 12.1.10.3.2 Deals
      • 12.1.10.3.3 Expansions
  • 12.1.11 SYNTERMED INC.
    • 12.1.11.1 Business overview
    • 12.1.11.2 Products offered
    • 12.1.11.3 Recent developments
      • 12.1.11.3.1 Deals
  • 12.1.12 ULTRASPECT INC.
    • 12.1.12.1 Business overview
    • 12.1.12.2 Products offered
  • 12.1.13 LABLOGIC SYSTEMS LTD.
    • 12.1.13.1 Business overview
    • 12.1.13.2 Products offered
    • 12.1.13.3 Recent developments
      • 12.1.13.3.1 Product launches and approvals
      • 12.1.13.3.2 Deals
      • 12.1.13.3.3 Expansions
  • 12.1.14 MEDISO LTD.
    • 12.1.14.1 Business overview
    • 12.1.14.2 Products offered
    • 12.1.14.3 Recent developments
      • 12.1.14.3.1 Product launches and approvals
  • 12.1.15 CATALYST MEDTECH
    • 12.1.15.1 Business overview
    • 12.1.15.2 Products offered
    • 12.1.15.3 Recent developments
      • 12.1.15.3.1 Deals
      • 12.1.15.3.2 Other developments
  • 12.1.16 LEMER PAX
    • 12.1.16.1 Business overview
    • 12.1.16.2 Products offered
    • 12.1.16.3 Recent developments
      • 12.1.16.3.1 Product launches and approvals
      • 12.1.16.3.2 Deals
  • 12.1.17 SPECTRUM DYNAMICS MEDICAL
    • 12.1.17.1 Business overview
    • 12.1.17.2 Products offered
    • 12.1.17.3 Recent developments
      • 12.1.17.3.1 Product launches and approvals
      • 12.1.17.3.2 Deals
  • 12.1.18 NEUSOFT MEDICAL SYSTEMS CO., LTD.
    • 12.1.18.1 Business overview
    • 12.1.18.2 Recent developments
      • 12.1.18.2.1 Product launches and approvals
      • 12.1.18.2.2 Deals
  • 12.1.19 BRAINLAB SE
    • 12.1.19.1 Business overview
    • 12.1.19.2 Products offered
    • 12.1.19.3 Recent developments
      • 12.1.19.3.1 Product launches and approvals
      • 12.1.19.3.2 Deals
  • 12.1.20 MIRADA MEDICAL
    • 12.1.20.1 Business overview
    • 12.1.20.2 Products offered
    • 12.1.20.3 Recent developments
      • 12.1.20.3.1 Product launches and approvals
      • 12.1.20.3.2 Deals
• 12.2 OTHER PLAYERS
  • 12.2.1 TRASIS
  • 12.2.2 SOFIE
  • 12.2.3 ITM ISOTOPE TECHNOLOGIES MUNICH SE
  • 12.2.4 POSITRIGO AG
  • 12.2.5 PAIRE

13 APPENDIX

• 13.1 DISCUSSION GUIDE
• 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 13.3 CUSTOMIZATION OPTIONS
• 13.4 RELATED REPORTS
• 13.5 AUTHOR DETAILS

관련자료